Clinical Trials Browser

Phase 2/3 × Unknown × Neoplasm, Residual × Clear all

NCT03662087 2018-09-07

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Phase 2/3 Unknown

Neoplasm, Residual

NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Phase 2/3 Unknown

Neoplasm, Residual